Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Buy” by Brokerages

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been assigned a consensus rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $30.50.

A number of analysts have recently commented on TYRA shares. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Tuesday, February 18th. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective for the company.

Tyra Biosciences Stock Down 6.2 %

Shares of Tyra Biosciences stock opened at $12.03 on Wednesday. The firm has a market cap of $608.72 million, a PE ratio of -7.47 and a beta of 1.05. The business’s fifty day moving average is $14.37 and its two-hundred day moving average is $18.05. Tyra Biosciences has a fifty-two week low of $11.89 and a fifty-two week high of $29.60.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total value of $65,325.48. Following the completion of the sale, the director now directly owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 21,998 shares of company stock worth $344,818. Corporate insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new stake in Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences during the fourth quarter valued at about $50,000. BNP Paribas Financial Markets acquired a new stake in shares of Tyra Biosciences during the fourth quarter valued at about $60,000. Aquatic Capital Management LLC acquired a new stake in shares of Tyra Biosciences during the fourth quarter valued at about $64,000. Finally, Wells Fargo & Company MN grew its stake in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock valued at $132,000 after acquiring an additional 3,236 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.